Novo Nordisk Instant Savings Card

Details of Offer Including Restrictions on Eligibility and Other Limitations

You are not eligible for this savings offer if you are enrolled in or participate in Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program (each a Government Program), or where prohibited by state law. The Federal Employees Health Benefits (FEHB) Program is not a Government Program for the purposes of this savings program. You must not submit, or have submitted on your behalf by a pharmacist or other third party, a claim for reimbursement or coverage to any Government Program for items purchased with this savings card.

Program terms and conditions:

  • Pay no more than $25 when you start on a Novo Nordisk product, and no more than $20 for the next prescribed product and each refill for up to 2 years. Novo Nordisk will pay up to $100 of your co-pay for each of your first 24 prescription fills for 2 years from the time of initial card activation. Eligibility and other restrictions apply. Novo Nordisk reserves the right to modify or cancel this program at any time. If your co-pay is already $25 or less for your first prescribed Novo Nordisk product or $20 or less for your next prescribed Novo Nordisk product, this offer does not apply.
  • Get 1 free box of Novo Nordisk needles when you activate your Savings Card and enroll in the program. Maximum savings of $60. Limit 1 box of needles per person. Needles are sold separately and may require a prescription in some states. Needles must not be shared.
  • Offer good only in the USA, Puerto Rico, Guam, Saipan and Virgin Islands at participating retail pharmacies and cannot be redeemed at government-subsidized clinics. Void where taxed, restricted, or prohibited by law.
  • Absent a change in Massachusetts law, effective July 1, 2017, the Savings Card will no longer be valid for residents of Massachusetts.
  • Patients must be enrolled in a commercial insurance plan. Offer excludes full cash-paying patients.
  • Patient is responsible for complying with any insurance carrier co-payment disclosure requirements, including disclosing any savings received from this program.
  • Re-confirmation of information may be requested periodically to ensure accuracy of data and compliance with terms.
  • Patient must be 18 years of age or older to redeem the Savings Card.
  • Participating patients must re-present their Novo Nordisk Instant Savings Card if changing pharmacies.
  • This offer is limited to 1 card per patient. This card is not transferable.
  • The Novo Nordisk Instant Savings Card may be used for mail order.
  • Participating pharmacists must comply with all applicable laws and contractual or other obligations as a pharmacy provider.
  • Participating patients and pharmacists understand and agree to comply with the terms and conditions of this offer as set forth herein.
  • This savings program cannot be combined with any other coupon, certificate, voucher, or similar offer.
  • This is not an insurance program.

Selected Important Safety Information

Contraindications

  • NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. 

Warnings and Precautions

  • Never Share a NovoLog® FlexPen, NovoLog® FlexTouch®, PenFill® Cartridge, or PenFill® Cartridge Device Between Patients, even if the needle is changed. Patients using NovoLog® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. 
  • Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased.

NovoLog® (insulin aspart injection) 100 U/mL Indications and Usage

NovoLog® (insulin aspart injection) 100 U/mL is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. 

Important Safety Information

Contraindications

  • NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. 

Warnings and Precautions

  • Never Share a NovoLog® FlexPen, NovoLog® FlexTouch®, PenFill® Cartridge, or PenFill® Cartridge Device Between Patients, even if the needle is changed. Patients using NovoLog® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. 
  • Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. 
  • Hypoglycemia is the most common adverse effect of insulin therapy. The timing of hypoglycemia may reflect the time-action profile of the insulin formulation. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. 
  • To avoid medication errors and accidental mix-ups between NovoLog® and other insulin products, instruct patients to always check the insulin label before injection. 
  • Severe, life-threatening, generalized allergy, including anaphylaxis, may occur with insulin products, including NovoLog®
  • As with all insulins, NovoLog® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death.  Monitor potassium levels in patients at risk for hypokalemia and treat if indicated.
  • Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including NovoLog®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered. 
  • Malfunction of the insulin pump or insulin infusion set or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis. Patients using insulin infusion pump therapy must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure. 

NovoLog® continuous subcutaneous infusion route (insulin pump): Do not mix NovoLog® with any other insulin or diluent. 

Adverse Reactions

  • Adverse reactions observed with NovoLog® include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. 

Use in Specific Populations

  • NovoLog® has not been studied in children with type 2 diabetes or in children with type 1 diabetes who are younger than 2 years of age. 
  • Like all insulins, NovoLog® requirements may be reduced in patients with renal impairment or hepatic impairment. These patients may require more frequent blood glucose monitoring and dose adjustments. 

Please click here for Prescribing Information.